COMMENTPrice is key for wider market adoption of Amgen’s AmjevitaWegovy: the latest weight loss fadPROTAC development gains momentum, but clinical performance is poorFDA head Califf on tighter accelerated approvals and lower drug pricesREGULATORY4D Molecular’s Fabry gene therapy program on FDA clinical holdThe company paused the enrolment of patients on two of its trials for 4D-310 last month following a ‘significant’ adverse event.insightEurope reports the highest prevalence of chronic coughcommentCould vaccine hesitancy impact hearing disorders?Price is key for wider market adoption of Amgen’s AmjevitaWegovy: the latest weight loss fadPROTAC development gains momentum, but clinical performance is poorFDA head Califf on tighter accelerated approvals and lower drug prices02/24/2024 06:59:49
Price is key for wider market adoption of Amgen’s Amjevita
Wegovy: the latest weight loss fad
PROTAC development gains momentum, but clinical performance is poor
FDA head Califf on tighter accelerated approvals and lower drug prices